.jpg?format=webp&width=780)
A phase 2a trial investigated the efficacy of peresolimab, a monoclonal antibody that stimulates the programmed cell death protein 1 (PD-1) pathway, in patients with moderate-to-severe rheumatoid arthritis. The trial involved adult patients who had an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (DMARDs) or biologic/targeted synthetic DMARDs. Patients were randomized to receive either 700 mg or 300 mg of peresolimab or a placebo intravenously every 4 weeks. The primary outcome measured the change in Disease Activity Score for 28 joints (DAS28-CRP) from baseline to week 12. The study found that the 700-mg dose of peresolimab showed significant efficacy compared to the placebo in reducing disease activity in rheumatoid arthritis patients. Secondary outcomes favored the 700-mg dose for certain response measures. The study suggests that PD-1 receptor stimulation has potential as a treatment for rheumatoid arthritis.
Like
Save
Share